Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.
Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-atherosclerotic activity in preclinical studies. The drug can act at several stages within the atherosclerotic process, utilising its antihypertensive and antioxidant properties to protect hypertensive animals against mortality and vascular damage, to reduce cholesterol levels from the vessel wall of hypercholesterolaemic animals, and to reduce the progression of existing atherosclerotic lesions. The clinical benefit of lacidipine in atherosclerosis has recently been confirmed in humans in a large, multicentre, comparative, 4-year clinical trial involving patients with mild to moderate hypertension. The European Lacidipine Study on Atherosclerosis (ELSA) showed that lacidipine was able to slow the progression of atherosclerosis, measured as carotid intimato-media thickness, by 40% compared with atenolol (p = 0.0073). Although further comparative trials are needed, based on the results of ELSA, lacidipine is likely to become a promising therapeutic agent for atherosclerosis.
Haller
H
H
Cardiovascular Center, University Hospital, Institute of Physiology, University of Zurich, Zurich, Switzerland.
Cosentino
F
F
Lüscher
T F
TF
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D006224:Cricetinae; D004095:Dihydropyridines / Q000494:pharmacology / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000473:pathology*; D006801:Humans; D051379:Mice; D011817:Rabbits
D000975:Antioxidants; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C060285:lacidipine